Alpha-Fetoprotein (AFP)
| Clinical | Optimal | |
|---|---|---|
| Male | 0.0 - 7.0 kU/L | <7.0 kU/L |
| Female | 0.0 - 7.0 kU/L (not applicable during pregnancy) | <7.0 kU/L |
What is Alpha-Fetoprotein (AFP)?
Alpha-Fetoprotein (AFP) is a glycoprotein produced in large quantities by the foetal liver and yolk sac during pregnancy. In healthy adults, AFP levels are normally very low. Elevated levels in non-pregnant adults can be associated with liver disease, liver cancer (hepatocellular carcinoma), and certain germ cell tumours.
AFP is used clinically in several contexts: as a tumour marker for hepatocellular carcinoma (HCC), for monitoring germ cell tumours of the testes and ovaries, as part of prenatal screening (maternal serum AFP), and for surveillance of patients with chronic liver disease who are at increased risk of developing liver cancer.
The test measures AFP concentration in the blood. While it is a useful tool for monitoring known conditions, it is not sensitive or specific enough to be used as a standalone screening test for cancer in the general population.
Why Alpha-Fetoprotein (AFP) Matters for Your Health
Liver cancer is one of the fastest-rising cancers in the UK, driven largely by increasing rates of fatty liver disease and chronic hepatitis. For individuals with known chronic liver disease (viral hepatitis B or C, cirrhosis, non-alcoholic fatty liver disease), AFP monitoring alongside liver ultrasound forms part of the recommended surveillance for early hepatocellular carcinoma detection.
For general health monitoring, AFP provides insight into liver health beyond standard liver function tests. Mildly elevated AFP can occur in chronic hepatitis and cirrhosis without cancer, reflecting liver regeneration and inflammation.
In the context of testicular cancer (the most common cancer in young men in the UK), AFP is one of the key tumour markers used for diagnosis, staging, and monitoring treatment response.
Alpha-Fetoprotein (AFP)& Your Wearable Data
Alpha-fetoprotein (AFP) is a tumour marker used to screen for and monitor hepatocellular carcinoma (liver cancer) and certain germ cell tumours. AFP is also naturally elevated during pregnancy. In non-pregnant adults, persistently elevated AFP warrants investigation for liver pathology.
While wearable data has no direct relationship with AFP levels, overall health monitoring through your wearable supports liver health through regular exercise and healthy lifestyle tracking. Individuals with chronic liver conditions who are monitoring AFP should maintain the active lifestyle and healthy habits tracked by their wearable, as regular physical activity is associated with reduced liver cancer risk.
What High Alpha-Fetoprotein (AFP) May Suggest
Elevated AFP in non-pregnant adults may suggest hepatocellular carcinoma, germ cell tumours (testicular or ovarian), chronic hepatitis, liver cirrhosis, or other liver pathology. Pregnancy is the most common physiological cause of elevated AFP.
Modestly elevated AFP (7–20 kU/L) is commonly seen in chronic liver disease due to ongoing liver cell regeneration and does not necessarily indicate cancer. However, significantly elevated levels (above 200 kU/L) in the context of a liver mass are highly suggestive of hepatocellular carcinoma.
If results suggest elevated AFP, your GP will typically arrange liver imaging (ultrasound, CT, or MRI) and further blood tests. The clinical context, including liver disease history, symptoms, and imaging findings, guides further management.
What Low Alpha-Fetoprotein (AFP) May Suggest
Low or normal AFP levels are the expected finding in healthy adults and are generally reassuring. However, a normal AFP does not exclude liver cancer, as up to 40% of small hepatocellular carcinomas may not produce elevated AFP.
In patients being monitored after treatment for AFP-producing tumours, sustained normal AFP levels suggest successful treatment and are a positive finding.
Normal AFP requires no specific follow-up in the general population.
How to Optimise Your Alpha-Fetoprotein (AFP)
Food
Support liver health with a diet rich in vegetables, fruits, whole grains, and lean proteins. Include liver-protective foods such as coffee (which has strong evidence for reducing liver disease risk), garlic, and artichokes. Consume cruciferous vegetables for their support of liver detoxification pathways. Include turmeric (curcumin) for its anti-inflammatory and liver-protective properties. Avoid excessive alcohol, processed foods, and added sugars, which burden the liver.
Lifestyle
Moderate alcohol consumption or abstain entirely if you have existing liver concerns. Maintain a healthy weight to reduce the risk of non-alcoholic fatty liver disease, which is now the most common chronic liver condition in the UK. Exercise regularly, as physical activity helps reduce liver fat. Ensure vaccination against hepatitis B if not already immunised. Practise safe behaviours to reduce hepatitis B and C transmission risk. Avoid unnecessary use of medications that stress the liver, including excessive paracetamol.
Supplements
Milk thistle (silymarin, 200–400 mg daily) has a long history of traditional use for liver support and some evidence for hepatoprotective effects. N-acetylcysteine (NAC) supports liver glutathione levels, the body's primary liver antioxidant. Vitamin E (alpha-tocopherol) has shown benefit in non-alcoholic fatty liver disease under medical supervision.
When to Speak to Your GP
See your GP if AFP is elevated above the reference range, particularly if you have risk factors for liver disease or a history of chronic hepatitis. Significantly elevated AFP (above 20 kU/L) requires prompt liver imaging. Young men with elevated AFP alongside a testicular lump or swelling should seek urgent assessment. Anyone with known liver cirrhosis should participate in regular AFP and ultrasound surveillance as recommended by their specialist.
References
- NHS. Liver cancer — Overview. Updated 2024. nhs.uk
- NICE. Suspected cancer: recognition and referral. NG12. nice.org.uk
- BSG. Heimbach JK, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380. pubmed.ncbi.nlm.nih.gov
- Lancet. Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. pubmed.ncbi.nlm.nih.gov
Medical Disclaimer— This content is for general educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Omniwo Ltd is a wellness information service and is not a medical device, clinical laboratory, or regulated healthcare provider under MHRA guidelines. The “optimal ranges” presented on this page are based on published clinical guidelines (WHO, NICE, NHS) and peer-reviewed research; they represent functional wellness targets and may differ from standard laboratory reference ranges. Individual results should always be interpreted by a qualified healthcare professional (such as your GP) who understands your full medical history. Do not start, stop, or change any medication or supplement based solely on this information. If you are experiencing symptoms, seek medical attention promptly.